These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 21546199)

  • 1. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria.
    Pfaller MA; Andes D; Arendrup MC; Diekema DJ; Espinel-Ingroff A; Alexander BD; Brown SD; Chaturvedi V; Fowler CL; Ghannoum MA; Johnson EM; Knapp CC; Motyl MR; Ostrosky-Zeichner L; Walsh TJ
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):330-43. PubMed ID: 21546199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Sensititre YeastOne colorimetric antifungal panel with CLSI microdilution for antifungal susceptibility testing of the echinocandins against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Chaturvedi V; Diekema DJ; Ghannoum MA; Holliday NM; Killian SB; Knapp CC; Messer SA; Miskou A; Ramani R
    Diagn Microbiol Infect Dis; 2012 Aug; 73(4):365-8. PubMed ID: 22726528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro fluconazole and voriconazole susceptibilities of Candida bloodstream isolates in Korea: use of the CLSI and EUCAST epidemiological cutoff values.
    Jang MJ; Shin JH; Lee WG; Kim MN; Lee K; Lee HS; Lee MK; Chang CL; Jang HC; Song ES; Kim SH; Shin MG; Suh SP; Ryang DW
    Ann Lab Med; 2013 May; 33(3):167-73. PubMed ID: 23667842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Feb; 49(2):630-7. PubMed ID: 21159940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values.
    Pfaller MA; Espinel-Ingroff A; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Mar; 49(3):845-50. PubMed ID: 21227994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.
    Pfaller MA; Andes D; Diekema DJ; Espinel-Ingroff A; Sheehan D;
    Drug Resist Updat; 2010 Dec; 13(6):180-95. PubMed ID: 21050800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of micafungin MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) and Etest for Candida spp. isolates.
    Espinel-Ingroff A; Cantón E; Pelaez T; Pemán J
    Diagn Microbiol Infect Dis; 2011 May; 70(1):54-9. PubMed ID: 21513843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole.
    Lee SC; Lo HJ; Fung CP; Lee N; See LC
    J Microbiol Immunol Infect; 2009 Apr; 42(2):148-53. PubMed ID: 19597647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of voriconazole against Candida species isolated in Taiwan.
    Yang YL; Cheng HH; Lo HJ
    Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp.
    Pfaller MA; Castanheira M; Messer SA; Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2014 Jun; 79(2):198-204. PubMed ID: 24736096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal susceptibility of bloodstream yeasts isolated at a public children's hospital in Brazil: comparison of the Etest and the AFST-EUCAST microdilution method.
    Matsumoto FE; Dias AL; Melhem MS; Szeszs MW; Auler ME; Ruiz LS; Gonçalves da Silva E; Gandra RF; Paula CR
    Can J Microbiol; 2007 Dec; 53(12):1300-6. PubMed ID: 18059562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
    Fleck R; Dietz A; Hof H
    J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.
    Pfaller MA; Castanheira M; Diekema DJ; Messer SA; Jones RN
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):252-9. PubMed ID: 21917395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.